Developing biopharmaceutical formulations that offer maximum patient convenience without sacrificing safety and efficacy for entities such as mAbs, antibody drug conjugates, and Fc-conjugates among others is increasingly complex.. Many drugs now require doses for subcutaneous delivery beyond what can be achieved with a 1 mL injection of an aqueous formulation. A significant hurdle in meeting..